These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 16530575)

  • 61. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.
    Asiimwe F; Moore D; Were W; Nakityo R; Campbell J; Barasa A; Mermin J; Kaharuza F
    HIV Med; 2012 Mar; 13(3):166-71. PubMed ID: 22112164
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies.
    Boulle A; Schomaker M; May MT; Hogg RS; Shepherd BE; Monge S; Keiser O; Lampe FC; Giddy J; Ndirangu J; Garone D; Fox M; Ingle SM; Reiss P; Dabis F; Costagliola D; Castagna A; Ehren K; Campbell C; Gill MJ; Saag M; Justice AC; Guest J; Crane HM; Egger M; Sterne JA
    PLoS Med; 2014 Sep; 11(9):e1001718. PubMed ID: 25203931
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.
    Rouet F; Fassinou P; Inwoley A; Anaky MF; Kouakoussui A; Rouzioux C; Blanche S; Msellati P;
    AIDS; 2006 Nov; 20(18):2315-9. PubMed ID: 17117017
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment outcome of HAART-treated patients in a resource-limited setting: the Belgrade Cohort Study.
    Jevtović D; Dragovic G; Salemović D; Ranin J; Kušić J; Marinković J; Djurković-Djaković O
    Biomed Pharmacother; 2014 Apr; 68(3):391-5. PubMed ID: 24486106
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.
    Cornell M; Schomaker M; Garone DB; Giddy J; Hoffmann CJ; Lessells R; Maskew M; Prozesky H; Wood R; Johnson LF; Egger M; Boulle A; Myer L;
    PLoS Med; 2012; 9(9):e1001304. PubMed ID: 22973181
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries.
    Sow PS; Otieno LF; Bissagnene E; Kityo C; Bennink R; Clevenbergh P; Wit FW; Waalberg E; Rinke de Wit TF; Lange JM;
    J Acquir Immune Defic Syndr; 2007 Mar; 44(3):262-7. PubMed ID: 17146376
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand.
    Fregonese F; Collins IJ; Jourdain G; Lecoeur S; Cressey TR; Ngo-Giang-Houng N; Banchongkit S; Chutanunta A; Techapornroong M; Lallemant M;
    J Acquir Immune Defic Syndr; 2012 May; 60(1):91-8. PubMed ID: 22293548
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance.
    Weidle PJ; Malamba S; Mwebaze R; Sozi C; Rukundo G; Downing R; Hanson D; Ochola D; Mugyenyi P; Mermin J; Samb B; Lackritz E
    Lancet; 2002 Jul; 360(9326):34-40. PubMed ID: 12114039
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.
    Agwu A; Lindsey JC; Ferguson K; Zhang H; Spector S; Rudy BJ; Ray SC; Douglas SD; Flynn PM; Persaud D;
    AIDS Patient Care STDS; 2008 Jul; 22(7):545-52. PubMed ID: 18479228
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997-2011.
    Martin DA; Luz PM; Lake JE; Clark JL; Veloso VG; Moreira RI; Cardoso SW; Klausner JD; Grinsztejn B
    BMC Infect Dis; 2014 Jun; 14():322. PubMed ID: 24919778
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.
    Antiretroviral Therapy Cohort Collaboration
    Lancet; 2008 Jul; 372(9635):293-9. PubMed ID: 18657708
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa.
    Barth RE; van der Meer JT; Hoepelman AI; Schrooders PA; van de Vijver DA; Geelen SP; Tempelman HA
    Eur J Clin Microbiol Infect Dis; 2008 Oct; 27(10):977-84. PubMed ID: 18629557
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study.
    Edmonds A; Yotebieng M; Lusiama J; Matumona Y; Kitetele F; Napravnik S; Cole SR; Van Rie A; Behets F
    PLoS Med; 2011 Jun; 8(6):e1001044. PubMed ID: 21695087
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.
    Palella FJ; Baker RK; Moorman AC; Chmiel JS; Wood KC; Brooks JT; Holmberg SD;
    J Acquir Immune Defic Syndr; 2006 Sep; 43(1):27-34. PubMed ID: 16878047
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [The evaluation of four-year highly active antiretroviral therapy in HIV-1 infected patients].
    Deng XJ; He Y; Yang L; Zou SP; Yang H; Zheng YH
    Zhonghua Nei Ke Za Zhi; 2011 Mar; 50(3):230-4. PubMed ID: 21600088
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population.
    Jensen-Fangel S; Pedersen L; Pedersen C; Larsen CS; Tauris P; Møller A; Sørensen HT; Obel N
    AIDS; 2004 Jan; 18(1):89-97. PubMed ID: 15090834
    [TBL] [Abstract][Full Text] [Related]  

  • 79. All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART).
    Kim JH; Psevdos G; Gonzalez E; Singh S; Kilayko MC; Sharp V
    Infection; 2013 Apr; 41(2):545-51. PubMed ID: 23264096
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Antiretroviral treatment for children.
    Eley B; Davies MA; Apolles P; Cowburn C; Buys H; Zampoli M; Finlayson H; King S; Nuttall J
    S Afr Med J; 2006 Sep; 96(9 Pt 2):988-93. PubMed ID: 17077930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.